Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ LILRA2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5101650
Description
Antibody detects endogenous levels of total LILRA2.
Leukocyte Ig-like receptors (LIRs) are a family of immunoreceptors expressed predominantly on monocytes and B cells and at lower levels on dendritic cells and natural killer (NK) cells. All LIRs in subfamily B have an inhibitory function (LILRB1; MIM 604811). LIRs in subfamily A, with short cytoplasmic domains lacking an immunoreceptor tyrosine-based inhibitory motif (ITIM) and with trans membrane regions containing a charged arginine residue, may initiate stimulatory cascades. One member of subfamily A (LILRA3; MIM 604818) lacks a transmembrane region and is presumed to be a soluble receptor.
Specifications
LILRA2 | |
Polyclonal | |
Unconjugated | |
LILRA2 | |
CD85 antigen-like family member H; CD85h; ILT1; ILT-1; Immunoglobulin-like transcript 1; leucocyte Ig-like receptor A2; leukocyte immunoglobulin like receptor A2; leukocyte immunoglobulin-like receptor 7; Leukocyte immunoglobulin-like receptor subfamily A member 2; leukocyte immunoglobulin-like receptor subfamily A member 2 soluble; leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2; LILRA2; LIR7; LIR-7 | |
Rabbit | |
Affinity chromatography | |
RUO | |
11027 | |
-20°C | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
Q8N149 | |
LILRA2 | |
A synthesized peptide derived from human LILRA2(Accession Q8N149), corresponding to amino acid residues P409-V459. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction